Liver resection for colorectal metastases after chemotherapy: Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival

Annals of Surgery

Volumn 258, Issue 5, 2013, Pages 731-742

  Viganò, Luca ^a   Capussotti, Lorenzo ^a   De Rosa, Giovanni ^a   De Saussure, Wassila Oulhaci ^b   Mentha, Gilles ^b   Rubbia Brandt, Laura ^c  

^a MAURIZIANO HOSPITAL   (Italy)

^b Department of Visceral and Transplantation Surgery ^*  (Italy)

^c UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adjuvant chemotherapy; Body mass index; Chemotherapy related liver injuries; Colorectal liver metastases; Liver surgery; Long term outcome; Micrometastases; Microscopic biliary invasion; Microvascular invasion; Neoadjuvant chemotherapy; Nodular regenerative hyperplasia; Pathological tumor response to chemotherapy; Preoperative chemotherapy; Prognostic factors; Sinusoidal dilatation; Sinusoidal obstruction syndrome; Steatohepatitis; Steatosis; Survival; Tumor regression grade

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

AGED; ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; FATTY LIVER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER HYPERPLASIA; LIVER INJURY; LIVER PARENCHYMA; LIVER RESECTION; LIVER VENOOCCLUSIVE DISEASE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; MORBIDITY; MULTIMODALITY CANCER THERAPY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RECTUM CANCER; SURGICAL MORTALITY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION; TUMOR REGRESSION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FATTY LIVER; FEMALE; HEPATECTOMY; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM INVASIVENESS; NEOPLASM MICROMETASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84886094086     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182a6183e     Document Type: Article

References (38)

1. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
2. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829-1835.
3. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016. (Pubitemid 351392040)
4. Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225-1239.
5. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-2072. (Pubitemid 46622116)
6. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118-124.
7. Wicherts DA, de Haas RJ, Sebagh M, et al. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol. 2011;18:659-669.
8. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299-304. (Pubitemid 46323097)
9. Blazer DG, III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344-5351.
10. Wakai T, Shirai Y, Sakata J, et al. Histologic evaluation of intrahepatic micrometastases in patients treated with or without neoadjuvant chemotherapy for colorectal carcinoma liver metastasis. Int J Clin Exp Pathol. 2012;5:308-314.
11. Yokoyama N, Shirai Y, Ajioka Y, et al. Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer. 2002;94:1642-1647. (Pubitemid 34241099)
12. Wakai T, Shirai Y, Sakata J, et al. Appraisal of 1 cm hepatectomy margins for intrahepatic micrometastases in patients with colorectal carcinoma liver metastasis. Ann Surg Oncol. 2008;15:2472-2481.
13. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460-466. (Pubitemid 38444550)
14. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321. (Pubitemid 40770284)
15. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787-797. (Pubitemid 20191384)
16. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686. (Pubitemid 24166250)
17. Vigaǹo L, Langella S, Ferrero A, et al. Colorectal cancer with synchronous resectable liver metastases: monocentric management in a hepatobiliary referral center improves survival outcomes. Ann Surg Oncol. 2013;20:938-945.
18. Mentha G, Majno PE, Andres A, et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93:872-878. (Pubitemid 44035261)
19. Andres A, Majno PE, Morel P, et al. Improved long-termoutcome of surgery for advanced colorectal livermetastases: reasons and implications formanagement on the basis of a severity score. Ann Surg Oncol. 2008;15:134-143.
20. Vigaǹo L, Russolillo N, Ferrero A, et al. Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades. Ann Surg Oncol. 2012;19:2035-2044.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
22. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213. (Pubitemid 38963009)
23. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007;246:183-191. (Pubitemid 47196514)
24. Gregoire E, Hoti E, Gorden DL, et al. Utility or futility of prognostic scoring systems for colorectal liver metastases in an era of advanced multimodal therapy. Eur J Surg Oncol. 2010;36:568-574.
25. Vigaǹo L, Capussotti L, Barroso E, et al. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases. Ann Surg Oncol. 2012;19:2786-2796.
26. Poultsides GA, Bao F, Servais EL, et al. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol. 2012;19:2797-2804.
27. Klinger M, Tamandl D, Eipeldauer S, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 2010;17:2059-2065.
28. Seium Y, Stupp R, Ruhstaller T, et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol. 2005;16:762-766. (Pubitemid 40767097)
29. Masi G, Vasile E, Loupakis F, et al. Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2008;7:7-14. (Pubitemid 351252446)
30. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635-1641.
31. Vreuls CP, Van Den Broek MA, Winstanley A, et al. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology. 2012;61:314-318.
32. Rubbia-Brandt L, Tauzin S, Brezault C, et al. Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther. 2011;10:687-696.
33. Tamandl D, Klinger M, Eipeldauer S, et al. Sinusoidal obstruction syndrome impairs long-termoutcome of colorectal livermetastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:421-430.
34. Pathak S, Tang JM, Terlizzo M, et al. Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastases. Eur J Surg Oncol. 2010;36:52-57.
35. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7: 1034-1044. (Pubitemid 37524071)
36. Parkin E, O'Reilly DA, Adam R, et al. The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy [published online ahead of print December 27, 2012]. HPB (Oxford). 2013;15:463-472.
37. Simkens LH, Koopman M, Mol L, et al. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur J Cancer. 2011;47:2560-2567.
38. Mathur AK, Ghaferi AA, Sell K, et al. Influence of body mass index on complications and oncologic outcomes following hepatectomy for malignancy. J Gastrointest Surg. 2010;14:849-857.